The healthcare sector faces great change and opportunities in delivering patient wellbeing.

Rapid innovation in personal health technology and personalised medicine is creating new ways to assist patients, along with new challenges for regulators and industry participants.

The pharmaceuticals and biotech industry is also adapting to deal with significant challenges, such as the patent cliff and the emergence of biosimilars.

As Australia’s population ages, new and profound challenges to the country's healthcare system are emerging. In this context, it is essential for policymakers to explore all the opportunities that new technologies make possible.

How we can help

Our clients are reimagining the delivery of services across the healthcare sector and we are working with them to navigate industry trends and meet the challenges ahead of them.

Creating a holistic and commercial strategy

We help leading businesses across healthcare services, pharmaceuticals and medical devices to manage transactions, investments and disputes, looking not only at the regulatory obligations, but also product liability, litigation, mergers and acquisitions, privacy, intellectual property, infrastructure and funds management.

A presence where you need us most

We maintain a network of specialist healthcare regulatory and compliance lawyers in key global jurisdictions to assist our clients in dealing with local legislative regimes – wherever they do business.


Healthscope Limited M&A and merger control

Acted for one of Australia's leading private healthcare operators on the $105 million sale of its Australian pathology operations to Crescent Capital Partners.

AstraZeneca commercialisation

Negotiated and drafted licence, commercialisation and supply agreements for a market ready product in oncology pain relief for which Australia is being used as a test market.

Mundipharma patent dispute

Successfully defended a challenge to the patent term extension for oxycontin, which kept generic competitors out of the market until the expiration of the full five year extended period.

Pfizer competition

Acted in proceedings commenced by the ACCC for alleged misuse of market power and exclusive dealing in relation to the supply of atorvastatin to pharmacies.

Compliance and regulatory

Pre- and post-acquisition reviews of marketing authorisations/drug approvals, labelling and promotional compliance and development of strategies to resolve non-compliance.

Healthe Care acquisition

Advised Archer Capital on its $240 million acquisition of Australian private hospital business Healthe Care from a CHAMP Ventures consortium, as well as the subsequent acquisition and disposal of various private hospitals and the acquisition of Brisbane Waters Private Hospital from Healthscope Limited.

Plenary Health Consortium bid

Advised the consortium on its bid to finance, design, construct and maintain the new main hospital building and community health facilities at the Royal North Shore Hospital.

Johnson & Johnson acquisition of Synthes

Acted on J&J's acquisition of Synthes, a significant issue in the clearance of which was an analysis of the procurement practices of the public and private hospital sectors and the role of the Prostheses List in assessing competition.

Medical Devices

Advising in relation to the regulatory aspects associated with marketing and patient support programs for therapeutic goods, including compliance with industry codes and ethical obligations.